• direct thrombin inhibitors ASK has been identified as an ASK

  2023-07-05

  

  ASK2 has been identified as an ASK1 binding protein (Wang et al., 1998). ASK1 supports the stability and active configuration of ASK2 in the heteromeric complex, while ASK2 has been found to activate ASK1 by direct phosphorylation (Takeda et al., 2007). Unlike ASK1, which is ubiquitously expressed i

• The incremental reduction albeit not statistically significa

  2023-07-05

  

  The incremental reduction, albeit not statistically significant, in collagen I with LCZ696 compared to perindopril treated animals, may therefore be related to a more compliant ventricle in LCZ696-treated animals. This is not so surprising given the incremental anti-fibrotic effect of the active met

• br Possible complementarity of trimming pathways Determining

  2023-07-05

  

  Possible complementarity of trimming pathways Determining the exact pathway for the generation or destruction of MHCI peptide ligands by ERAP1 is important for our understanding of the shaping of the immunopeptidome and for designing inhibitors that can manipulate it. It is also possible however

• br Parkinson s Disease and the

  2023-07-05

  

  Parkinson’s Disease and the immune system Parkinson’s Disease (PD) is the second most common neurodegenerative disorder, after Alzheimer’s, which affects 10 million people globally and is characterized by rigidity, bradykinesia, tremors, and gait instability (O’sullivan et al., 2007). The patholo

• The physiologic conditions and signaling mechanisms

  2023-06-28

  

  The physiologic conditions and signaling mechanisms that regulate apelin secretion and APLNR expression in malignant tissues appear to be multifactorial. Previous studies have shown that hyperplastic and neoplastic cholangiocytes secrete a variety of hormones, peptides, and growth factors that help

• Various antiangiogenic drugs have been analyzed

  2023-06-27

  

  Various antiangiogenic drugs have been analyzed over the last few years; noteworthy, bevacizumab, a monoclonal antibody against VEGF-A, alone or in combination with cytotoxic agents showed interesting results in terms of radiographic response rates and progression-free survival in initial phase 2 st

• Various antiangiogenic drugs have been analyzed

  2023-06-27

  

  Various antiangiogenic drugs have been analyzed over the last few years; noteworthy, bevacizumab, a monoclonal antibody against VEGF-A, alone or in combination with cytotoxic agents showed interesting results in terms of radiographic response rates and progression-free survival in initial phase 2 st

• br Results and discussion In order to investigate the

  2023-06-26

  

  Results and discussion In order to investigate the assembly dynamics and aggregate structures of Aβ16-22, twelve molecular systems with the number of peptides varying from 1 to 12 were studied. In all simulations, the same peptide concentration (~15 mM) was maintained by adjusting the dimensions

• br ACh and ER tests hereafter Spasm provocation tests

  2023-06-15

  

  ACh and ER tests hereafter Spasm provocation tests have self-limitations to document coronary artery spasm during daily life. In the past reports, ST elevation was reproducible in some patients with variant U-104 mg by the administration of ACh or ER. However, we now employ the ER and ACh spasm

• Regarding brain tumors AXL has been implicated in gliomagene

  2023-06-13

  

  Regarding SC 79 tumors, AXL has been implicated in gliomagenesis and chemoresistance [39]. Previous investigations found that AXL is constitutively phosphorylated in many glioma cell lines, murine xenograft tumors and primary patient tumor samples [40]. Immunohistochemical analysis of AXL and Gas6

• Sorafenib was the first small RTK inhibitor drug to

  2023-06-07

  

  Sorafenib was the first small RTK inhibitor drug to be developed and was initially approved against renal cell carcinoma, then against hepatocellular carcinoma (HCC) and more recently for differentiated thyroid treatment [111]. Sunitinib soon followed, being approved for gastrointestinal stromal tum

• Sorafenib was the first small RTK inhibitor drug to

  2023-06-07

  

  Sorafenib was the first small RTK inhibitor drug to be developed and was initially approved against renal cell carcinoma, then against hepatocellular carcinoma (HCC) and more recently for differentiated thyroid treatment [111]. Sunitinib soon followed, being approved for gastrointestinal stromal tum

• Fish aminopeptidases from Alaska Pollack roe and tuna

  2023-06-05

  

  Fish aminopeptidases from Alaska Pollack roe and tuna pyloric caeca have been reported on [12,13]. More recently, we described the purification of a leucine aminopeptidase from the skeletal muscle of the common carp [14], red sea bream [15] and a lysine aminopeptidases from Japanese flounder [16]. T

• Fish aminopeptidases from Alaska Pollack roe and tuna

  2023-06-05

  

  Fish aminopeptidases from Alaska Pollack roe and tuna pyloric caeca have been reported on [12,13]. More recently, we described the purification of a leucine aminopeptidase from the skeletal muscle of the common carp [14], red sea bream [15] and a lysine aminopeptidases from Japanese flounder [16]. T

• A high throughput small molecule ACK biochemical

  2023-05-31

  

  A high-throughput small molecule ACK1 biochemical inhibition screen was performed in-house and led to the identification of 1μM inhibitor furanopyrimidine (). Further binding studies found DPQ to be both ATP-competitive and reversible. Early structure-activity relationship (SAR) work was performe

14555 records 295/971 page Previous Next First page 上5页 291292293294295 下5页 Last page